Abstract | BACKGROUND: PATIENTS AND METHODS: Since July 2007, 10 progressive advanced chordoma patients with secondary resistance to IM, and biochemical and/or immunohistochemical evidence of upstream and/or downstream mTOR effector activation, started IM (400 mg/day) plus sirolimus (2 mg/day) on a named basis. RESULTS: The mean treatment duration was 9 months. Of nine patients assessable for response, at 3 months, we had one RECIST partial response (PR), seven stable disease (SD) and one progressive disease (PD). According to Choi criteria applied even to magnetic resonance imaging, we had seven PR (> or =10% decrease in size in four cases), one SD and one PD. Seven patients had a positron emission tomography response. The clinical benefit [RECIST complete response + PR + SD > or =6 months] was 89%. Pretreatment mTOR effectors analysis carried out in nine cases was positive in all patients (AKT activation in six patients, S6Sp6 expression/activation in seven). Post-treatment biopsy in one responsive patient confirmed S6 switch off. CONCLUSION:
|
Authors | S Stacchiotti, A Marrari, E Tamborini, E Palassini, E Virdis, A Messina, F Crippa, C Morosi, A Gronchi, S Pilotti, P G Casali |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 20
Issue 11
Pg. 1886-94
(Nov 2009)
ISSN: 1569-8041 [Electronic] England |
PMID | 19570961
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzamides
- Piperazines
- Pyrimidines
- Imatinib Mesylate
- Oncogene Protein v-akt
- Sirolimus
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Benzamides
- Blotting, Western
- Chordoma
(drug therapy, pathology)
- Female
- Humans
- Imatinib Mesylate
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Oncogene Protein v-akt
(biosynthesis, drug effects)
- Piperazines
(administration & dosage, adverse effects)
- Pyrimidines
(administration & dosage, adverse effects)
- Sacrum
(pathology)
- Sirolimus
(administration & dosage, adverse effects)
- Skull Base Neoplasms
(drug therapy, pathology)
- Spinal Neoplasms
(drug therapy, pathology)
- Treatment Outcome
- Young Adult
|